Moderna, Inc. (MRNA) SEC Filings & Earnings Calls

Key executive departure (CTO) may cause transitional risk in manufacturing operations.

“Jerh Collins, Ph.D., CTO and Quality Officer, retires after four years; transition to new COO oversight.”

High leverage and potential dilution from convertible notes; interest expense risk despite zero coupon.

“$2.6B convertible notes due 2032 with capped call transactions; potential dilution upon conversion.”

Litigation Settlement Impact

“Third-party royalties included $6 million and $884 million for the three and six months ended June 30, 2026, respectively, related to the litigation settlement with Arbutus and Genevant and amortization of the associated intangible asset.” · word for word

Clinical Trial Setback

“Our Phase 3 safety and efficacy study of mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis.” · word for word

Cash Burn

“Net cash used in operating activities for the six months ended June 30, 2026 was $1.2 billion” · word for word

Product Revenue Concentration

“COVID vaccine sales remain the primary source of product revenue, with RSV and combination vaccines still early in commercialization.”

Norovirus vaccine failure; pipeline setback reduces future revenue potential.

“mRNA-1403 did not meet early success criteria; additional cohort enrollment needed.”

Revenue growth limited to 10%; COVID franchise declining; new product uptake uncertain.

“Revenue growth target up to 10%; COVID sales declining.”

Litigation settlement cash outflow

“Under the terms of the agreement, we agreed to make a lump sum payment of $950 million, which is payable in the third quarter of 2026. ... could be required to make an additional payment of up to $1.3 billion depending on the outcome.” · word for word

Continued net losses and cash burn

“We reported a net loss of $1.3 billion for the three months ended March 31, 2026 and net losses of $2.8 billion and $3.6 billion for the years 2025 and 2024, respectively.” · word for word

Inventory write-downs due to demand uncertainty

“Inventory write-downs of $38 million, primarily related to our finished and semi-finished COVID vaccine inventory and raw materials relative to updated demand forecasts, as well as shelf-life expiration and other adjustments.” · word for word

Litigation settlement risk; $950M cash outflow expected in Q3 2026.

“Litigation settlement-related expenses of $878M recognized; payment of $950M expected in Q3 2026.”

Revenue concentration and market contraction

“While revenue remained under pressure in a contracting market” · word for word

Stock option underwater risk for executives

“All stock options granted to named executive officers (“NEOs”) from 2021-2024 (inclusive) remain underwater.” · word for word

Low shareholder support for compensation

“In 2025, 77% of shareholders who voted at our Annual Meeting on our “say on pay” proposal supported the pay actions we took in the prior year.” · word for word

PSU performance risk

“The Committee approved a vesting of 50% of target at its February 2026 meeting for the 2023 PSUs.” · word for word

Significant cash outflow from settlement payments

“$950M noncontingent payment due July 2026; potential additional $1.3B contingent payment.”

Litigation appeal risk

“Moderna may appeal to Federal Circuit on § 1498 issue; outcome could affect total payment.”

CMV vaccine Phase 3 failure

“We conducted a cCMV Phase 3 study of mRNA-1647 in women of childbearing age and announced in October 2025 that the study failed to reach its primary clinical endpoint. The program in women of childbearing age was discontinued.” · word for word

Revenue concentration in COVID vaccines

“In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines.” · word for word

Regulatory uncertainty for flu vaccine

“In February 2026, in response to a prior Refusal-to-File letter, we engaged with the FDA in a Type A meeting and submitted an amended BLA outlining a revised regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional” · word for word

COVID vaccine revenue decline continues, no new blockbuster product to offset

“Full year revenue down 40% driven by lower COVID vaccine sales volume”

FDA refusal-to-file for influenza vaccine creates regulatory uncertainty

“Company received Refusal-to-File letter from U.S. FDA and has requested Type A meeting” · word for word

Regulatory setback for key pipeline asset; potential delay in US market entry for seasonal flu vaccine.

“Moderna expects the earliest potential approvals for mRNA-1010 to begin in late 2026 or early 2027, subject to those ongoing regulatory reviews.” · word for word

Revenue concentration in COVID vaccine franchise; declining demand post-pandemic

“2025 revenue ~$1.9B, down from peak levels; company pivoting to seasonal vaccine franchise”

Clinical trial and regulatory approval risk for pipeline candidates

“potential first approvals of flu and flu/COVID combination products in 2026; pivotal trial data readouts in oncology, rare disease” · word for word

Dependence on vaccine market and competition.

“International results varied by region, shaped in part by a competitor contract still in effect in Europe.” · word for word

High interest cost (SOFR + 5.50%) increases financial burden.

“The applicable margin is a percentage per annum of 5.50% for Term SOFR and 4.50% for the base rate.” · word for word

Covenant tied to market cap; if market cap falls below $5B, liquidity covenant applies, potentially restricting operations.

“The Financial Covenant is not required to be tested at any time in which the trailing 30 day average market capitalization of the Company exceeds $5,000,000,000.” · word for word

Delayed draw tranches contingent on regulatory milestones, adding uncertainty.

“contingent on the achievement of key regulatory milestones aligned with the Company’s late-stage clinical pipeline” · word for word

Clinical trial risk for Norovirus vaccine due to insufficient case accrual.

“The ongoing Phase 3 study has not accrued sufficient cases and is enrolling a second Northern Hemisphere season.” · word for word

Regulatory uncertainty for flu/COVID combination vaccine with FDA refiling guidance pending.

“The Company is awaiting further guidance from the U.S. FDA on refiling.” · word for word

COVID Vaccine Demand Decline

“Net product sales decreased by $847 million, or 47%, for the three-month period... primarily due to lower COVID vaccine sales in both the U.S. and international markets.” · word for word

Pipeline Failure - CMV Vaccine

“The study did not meet its primary efficacy endpoint of preventing CMV infection in seronegative female participants of childbearing age... We will discontinue our congenital CMV clinical development program.” · word for word

Cash Burn

“Net cash used in operating activities for the nine months ended September 30, 2025 was $2.8 billion.” · word for word

Declining COVID vaccine demand due to reduced vaccination rates and market saturation.

“Revenue decline primarily driven by lower COVID vaccine sales. Reduced vaccination rates year over year.”

Dependence on COVID vaccine for majority of revenue; RSV and pipeline products still nascent.

“COVID vaccine sales $971M out of $1.0B total revenue. RSV sales only $2M.”

Pipeline execution risk for flu vaccine and other candidates; regulatory approvals uncertain.

“Seasonal flu vaccine Phase 3 data presented; submissions for approval expected by January 2026.”